COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 09 07 2020
accepted: 03 12 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 12 1 2021
Statut: epublish

Résumé

Detailed temporal analyses of complete (full) blood count (CBC) parameters, their evolution and relationship to patient age, gender, co-morbidities and management outcomes in survivors and non-survivors with COVID-19 disease, could identify prognostic clinical biomarkers. From 29 January 2020 until 28 March 2020, we performed a longitudinal cohort study of COVID-19 inpatients at the Italian National Institute for Infectious Diseases, Rome, Italy. 9 CBC parameters were studied as continuous variables [neutrophils, lymphocytes, monocytes, platelets, mean platelet volume, red blood cell count, haemoglobin concentration, mean red blood cell volume and red blood cell distribution width (RDW %)]. Model-based punctual estimates, as average of all patients' values, and differences between survivors and non-survivors, overall, and by co-morbidities, at specific times after symptoms, with relative 95% CI and P-values, were obtained by marginal prediction and ANOVA- style joint tests. All analyses were carried out by STATA 15 statistical package. 379 COVID-19 patients [273 (72% were male; mean age was 61.67 (SD 15.60)] were enrolled and 1,805 measures per parameter were analysed. Neutrophils' counts were on average significantly higher in non-survivors than in survivors (P<0.001) and lymphocytes were on average higher in survivors (P<0.001). These differences were time dependent. Average platelets' counts (P<0.001) and median platelets' volume (P<0.001) were significantly different in survivors and non-survivors. The differences were time dependent and consistent with acute inflammation followed either by recovery or by death. Anaemia with anisocytosis was observed in the later phase of COVID-19 disease in non-survivors only. Mortality was significantly higher in patients with diabetes (OR = 3.28; 95%CI 1.51-7.13; p = 0.005), obesity (OR = 3.89; 95%CI 1.51-10.04; p = 0.010), chronic renal failure (OR = 9.23; 95%CI 3.49-24.36; p = 0.001), COPD (OR = 2.47; 95% IC 1.13-5.43; p = 0.033), cardiovascular diseases (OR = 4.46; 95%CI 2.25-8.86; p = 0.001), and those >60 years (OR = 4.21; 95%CI 1.82-9.77; p = 0.001). Age (OR = 2.59; 95%CI 1.04-6.45; p = 0.042), obesity (OR = 5.13; 95%CI 1.81-14.50; p = 0.002), renal chronic failure (OR = 5.20; 95%CI 1.80-14.97; p = 0.002) and cardiovascular diseases (OR 2.79; 95%CI 1.29-6.03; p = 0.009) were independently associated with poor clinical outcome at 30 days after symptoms' onset. Increased neutrophil counts, reduced lymphocyte counts, increased median platelet volume and anaemia with anisocytosis, are poor prognostic indicators for COVID19, after adjusting for the confounding effect of obesity, chronic renal failure, COPD, cardiovascular diseases and age >60 years.

Sections du résumé

BACKGROUND
Detailed temporal analyses of complete (full) blood count (CBC) parameters, their evolution and relationship to patient age, gender, co-morbidities and management outcomes in survivors and non-survivors with COVID-19 disease, could identify prognostic clinical biomarkers.
METHODS
From 29 January 2020 until 28 March 2020, we performed a longitudinal cohort study of COVID-19 inpatients at the Italian National Institute for Infectious Diseases, Rome, Italy. 9 CBC parameters were studied as continuous variables [neutrophils, lymphocytes, monocytes, platelets, mean platelet volume, red blood cell count, haemoglobin concentration, mean red blood cell volume and red blood cell distribution width (RDW %)]. Model-based punctual estimates, as average of all patients' values, and differences between survivors and non-survivors, overall, and by co-morbidities, at specific times after symptoms, with relative 95% CI and P-values, were obtained by marginal prediction and ANOVA- style joint tests. All analyses were carried out by STATA 15 statistical package.
MAIN FINDINGS
379 COVID-19 patients [273 (72% were male; mean age was 61.67 (SD 15.60)] were enrolled and 1,805 measures per parameter were analysed. Neutrophils' counts were on average significantly higher in non-survivors than in survivors (P<0.001) and lymphocytes were on average higher in survivors (P<0.001). These differences were time dependent. Average platelets' counts (P<0.001) and median platelets' volume (P<0.001) were significantly different in survivors and non-survivors. The differences were time dependent and consistent with acute inflammation followed either by recovery or by death. Anaemia with anisocytosis was observed in the later phase of COVID-19 disease in non-survivors only. Mortality was significantly higher in patients with diabetes (OR = 3.28; 95%CI 1.51-7.13; p = 0.005), obesity (OR = 3.89; 95%CI 1.51-10.04; p = 0.010), chronic renal failure (OR = 9.23; 95%CI 3.49-24.36; p = 0.001), COPD (OR = 2.47; 95% IC 1.13-5.43; p = 0.033), cardiovascular diseases (OR = 4.46; 95%CI 2.25-8.86; p = 0.001), and those >60 years (OR = 4.21; 95%CI 1.82-9.77; p = 0.001). Age (OR = 2.59; 95%CI 1.04-6.45; p = 0.042), obesity (OR = 5.13; 95%CI 1.81-14.50; p = 0.002), renal chronic failure (OR = 5.20; 95%CI 1.80-14.97; p = 0.002) and cardiovascular diseases (OR 2.79; 95%CI 1.29-6.03; p = 0.009) were independently associated with poor clinical outcome at 30 days after symptoms' onset.
INTERPRETATION
Increased neutrophil counts, reduced lymphocyte counts, increased median platelet volume and anaemia with anisocytosis, are poor prognostic indicators for COVID19, after adjusting for the confounding effect of obesity, chronic renal failure, COPD, cardiovascular diseases and age >60 years.

Identifiants

pubmed: 33370366
doi: 10.1371/journal.pone.0244129
pii: PONE-D-20-21231
pmc: PMC7769441
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0244129

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):e129-e137
pubmed: 27787339
Ann Hematol. 2020 Jun;99(6):1205-1208
pubmed: 32296910
Int J Rheum Dis. 2019 Jan;22(1):47-54
pubmed: 30168259
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Monaldi Arch Chest Dis. 2020 May 25;90(2):
pubmed: 32449614
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
PLoS One. 2018 Dec 11;13(12):e0208715
pubmed: 30533065
Nat Immunol. 2004 Feb;5(2):133-9
pubmed: 14749784
Eur J Immunol. 2010 Nov;40(11):2969-75
pubmed: 21061430
Int J Infect Dis. 2020 Apr;93:192-197
pubmed: 32112966
J Clin Invest. 2015 Dec;125(12):4692-8
pubmed: 26551684
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Clin Lab. 2019 Mar 1;65(3):
pubmed: 30868855
Clin Infect Dis. 2018 Jan 6;66(1):36-44
pubmed: 29020340
BMJ. 2003 Jun 21;326(7403):1358-62
pubmed: 12816821
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Am J Clin Pathol. 2019 Apr 2;151(5):446-451
pubmed: 30535132
Antimicrob Agents Chemother. 2014 May;58(5):2856-65
pubmed: 24614369
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1087-1089
pubmed: 32636199
J Thromb Haemost. 2020 Jun;18(6):1469-1472
pubmed: 32302435
Burns. 2019 Aug;45(5):1158-1163
pubmed: 30686695
Clin Infect Dis. 2020 Jul 28;71(15):786-792
pubmed: 32211755
Lancet. 2020 Mar 28;395(10229):1063-1077
pubmed: 32145185
Clin Infect Dis. 2018 Apr 17;66(9):1479-1480
pubmed: 29272400
Clin Infect Dis. 2020 Nov 19;71(16):2272-2275
pubmed: 32407466
Lancet Glob Health. 2020 May;8(5):e641-e642
pubmed: 32199072
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
BMC Infect Dis. 2014 Mar 05;14:129
pubmed: 24597687

Auteurs

Simone Lanini (S)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Chiara Montaldo (C)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Emanuele Nicastri (E)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Francesco Vairo (F)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Chiara Agrati (C)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Nicola Petrosillo (N)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Paola Scognamiglio (P)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Andrea Antinori (A)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Vincenzo Puro (V)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Antonino Di Caro (A)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Gabriella De Carli (G)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Assunta Navarra (A)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Alessandro Agresta (A)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Claudia Cimaglia (C)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Fabrizio Palmieri (F)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Gianpiero D'Offizi (G)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Luisa Marchioni (L)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Gary Pignac Kobinger (GP)

Centre de Recherche en Infectiologie de l'Université Laval, Quebec City, QC, Canada.

Markus Maeurer (M)

Champalimaud Centre for the Unknown, Lisbon, Portugal.
University of Mainz, Mainz, Germany.

Enrico Girardi (E)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Maria Rosaria Capobianchi (MR)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Alimuddin Zumla (A)

Department of Infection, Division of Infection and Immunity, University College London, London, United Kingdom.
NHS Foundation Trust, London, United Kingdom.

Franco Locatelli (F)

Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Giuseppe Ippolito (G)

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH